10878 results for 'cell vial assi'

For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-inducin

As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related di

Thanks to the great intuitions of brilliant scientists like Louis Pasteur, Edward Jenner, Robert Koch, Emil von Behring, Gaston Leon Ramon, Albert Sabin, Jonas Salk in the past century, the

Introduction to IL-10R and Immune Suppression in CancerThe interleukin-10 receptor (IL-10R) is a key player in regulating immune responses, particularly in suppressing inflammation and ma

Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking

Ralitsa R. Madsen – University of Cambridge Metabolic Research Laboratories Each one of us is the result of an extraordinary developmental proces

Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance

What are MHC Class I molecules? The MHC class I is a glycoprotein that is expressed on all nucleated cells of the human body. MHC class I are important in disease defense against viruses, ba

Lab Buffers · ProtocolsPBS vs DPBS: What’s the Difference?PBS and DPBS are the everyday isotonic, pH-balanced salt solutions used to wash, dilute and transport cells and proteins. This guide bre

Background I am a 3rd year PhD student in Trinity College Dublin and my project is very much an interdisciplinary one. I’m very lucky to get to work between two great labs, Dr. Aisling Dunn

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell

The antigen tells a CD4 T cell to respond; the cytokine tells it what kind of response to make. A naive CD4⁺ T cell leaving the thymus is uncommitted. Within about seventy-two hours of engaging TCR/C

By Charlotte O'Donnell PhD < As IL-33/ST2 is such a potent inducer of inflammation, it is not surprising that dysr

Immunology · Innate ImmunityInnate Immunity: Components, Functions & First Line of DefenceThe innate immune system is the body’s first line of defence — a fast, non-specific response built from physic

Fibroblasts, essential components of connective tissues, play vital roles in maintaining tissue structure and function. Their remarkable ability to produce and organize the extracellular matrix

Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu

Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r

What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express

Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel